| ID Source | ID |
|---|---|
| PubMed CID | 126377 |
| CHEMBL ID | 1214091 |
| SCHEMBL ID | 4918687 |
| MeSH ID | M0138490 |
| Synonym |
|---|
| CHEMBL1214091 |
| boc-phe-ser-arg-mca |
| 73554-90-2 |
| tert-butyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate |
| l-argininamide, n-((1,1-dimethylethoxy)carbonyl)-l-phenylalanyl-l-seryl-n-(4-methyl-2-oxo-2h-1-benzopyran-7-yl)- |
| tertiary-butyloxycarbonyl-phenylalanyl-seryl-arginyl-4-methylcoumarin-7-amide |
| t-butyloxycarbonyl-phe-ser-arg-mca |
| boc-phe-ser-arg-amc |
| SCHEMBL4918687 |
| boc-phe-ser-arg-amc acetate salt |
| JLKJMNJZJBEYLQ-SDHOMARFSA-N |
| boc-phe-ser-arg-4-methylcoumaryl-7-amide |
| DTXSID80994332 |
| 6-benzyl-12-(3-carbamimidamidopropyl)-4,7,10-trihydroxy-9-(hydroxymethyl)-2,2-dimethyl-n-(4-methyl-2-oxo-2h-1-benzopyran-7-yl)-3-oxa-5,8,11-triazatrideca-4,7,10-trien-13-imidic acid |
| tert-butyl (s)-1-((s)-1-((s)-5-guanidino-1-(4-methyl-2-oxo-2h-chromen-7-ylamino)-1-oxopentan-2-ylamino)-3-hydroxy-1-oxopropan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate |
| tert-butyl ((s)-1-(((s)-1-(((s)-5-guanidino-1-((4-methyl-2-oxo-2h-chromen-7-yl)amino)-1-oxopentan-2-yl)amino)-3-hydroxy-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate |
| CS-0455389 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| proteolysis | Transmembrane protease serine 11D | Homo sapiens (human) |
| respiratory gaseous exchange by respiratory system | Transmembrane protease serine 11D | Homo sapiens (human) |
| neural tube closure | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| proteolysis | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| protein catabolic process | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| keratinocyte differentiation | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| epithelial cell morphogenesis involved in placental branching | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| serine-type endopeptidase activity | Transmembrane protease serine 11D | Homo sapiens (human) |
| protein binding | Transmembrane protease serine 11D | Homo sapiens (human) |
| peptidase activity | Transmembrane protease serine 11D | Homo sapiens (human) |
| serine-type endopeptidase activity | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| serine-type peptidase activity | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Transmembrane protease serine 11D | Homo sapiens (human) |
| plasma membrane | Transmembrane protease serine 11D | Homo sapiens (human) |
| extracellular exosome | Transmembrane protease serine 11D | Homo sapiens (human) |
| extracellular space | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| plasma membrane | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| external side of plasma membrane | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| basolateral plasma membrane | Suppressor of tumorigenicity 14 protein | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID497561 | Ratio of Kcat to Km for bovine trypsin by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497554 | Activity at human HAT by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497559 | Ratio of Kcat to Km for human tryptase by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497560 | Activity at bovine trypsin by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497558 | Activity at human tryptase by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497557 | Ratio of Kcat to Km for human matriptase by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497555 | Ratio of Kcat to Km for human HAT by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| AID497556 | Activity at human matriptase by FRET assay | 2010 | Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15 | Substrate specificity and inhibitory study of human airway trypsin-like protease. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||